

**THE FOURTH INTERNATIONAL AIDS MALIGNANCY CONFERENCE**  
**Natcher Conference Center, National Institutes of Health, Bethesda, Maryland**  
**May 16-18, 2000**

**Program**

**May 16**

- 8:00 AM-6:00 PM     **POSTER PRESENTATIONS** (Abstract Numbers 11 to 34), First Floor Concourse
- 8:30 AM             Opening Remarks and Welcome  
Ellen Feigal, M.D., *National Cancer Institute*
- 8:45 AM             **PLENARY LECTURE**  
S1                    Harnessing the Immune System in the Fight Against AIDS  
Bruce Walker, M.D., *Harvard University*
- 9:10 AM             **ROUNDTABLE - Epidemiology of AIDS Malignancies**  
Chairs:  
Elizabeth Holly, M.D., *University of California, San Francisco*  
Jeffrey Jones, M.D., *Centers for Disease Control and Prevention*
- Panelists:  
S2                    International Collaboration on HIV and Cancer  
Gillian Reeves, Ph.D., *Imperial Cancer Research Fund, United Kingdom*  
Robert Newton, M.B.B.S., D.Phil., *Imperial Cancer Research Fund, United Kingdom*  
Valerie Beral, M.B.B.S., *Imperial Cancer Research Fund, United Kingdom*
- S3                    The National AIDS-Cancer Match Registry  
Robert Biggar, M.D., *National Cancer Institute*
- S4                    Risk for Hepatocellular Carcinoma and Non-Hodgkin's Lymphoma Among HIV-  
infected Adults  
Eric Engels, M.D., M.P.H., *National Cancer Institute*
- S5                    Human Papillomavirus-associated Anogenital Cancers in Patients with HIV Infection  
and AIDS  
Morten Frisch, M.D., Ph.D., *Statens Serum Institut, Denmark*
- 10:40 AM            Break
- 11:00 AM-11:45 AM **ABSTRACT PRESENTATIONS - AIDS Malignancies: Epidemiology and  
Immunology**  
Moderators:  
Robert Biggar, M.D., *National Cancer Institute*  
David Scadden, M.D. *Harvard University*

- 11:00 AM 1 National Linkage of HIV, AIDS, and Cancer Incidence Data  
Andrew Grulich, Ph.D., *National Centre in HIV Epidemiology and Clinical Research, Australia*
- 11:15 AM 2 The Spectrum of HIV-1 Related Cancers in South Africa  
Freddy Sitas, D.Phil., *National Cancer Registry, South Africa*
- 11:30 AM 3 Non-myeloablative Allogeneic Transplantation of Genetically Modified PBSCs for Hematologic Malignancies  
Elizabeth Kang, M.D., *National Institute of Diabetes and Digestive and Kidney Disorders*
- 11:45 AM Lunch (on your own)
- 1:15 PM **ROUNDTABLE - Kaposi's Sarcoma Herpesvirus (KSHV/HHV-8) Transmission In Vivo and In Vitro**  
Chairs:  
Harold Jaffe, M.D., *Centers for Disease Control and Prevention*  
Gary Hayward, Ph.D., *Johns Hopkins University*
- S6 In Vitro Transmission and Propagation of HHV-8 in Endothelial Cells  
Gary Hayward, Ph.D., *Johns Hopkins University*
- Panelists:
- S7 Transmission of HHV-8 Among Homosexual Men  
Jeffrey Martin, M.D., M.P.H., *University of California, San Francisco*
- S8 Natural History of HHV-8 Infection in an Endemic Population: Evidence for Mother-Child and Sibling-Sibling Transmission  
Antoine Gessain, M.D., Ph.D., *Pasteur Institute, France*
- S9 Evidence for Heterosexual Transmission of HHV-8 in South Africa  
Freddy Sitas, D.Phil., *Cancer Registry, South Africa*
- S10 HHV-8 Anatomic Sites, Shedding Patterns, Behavioral and Biological Risk Factors for Transmission  
Lawrence Corey, M.D., *University of Washington*
- S11 In Vitro Infection of Primary Human Endothelial, Epidermal, and Lymphoid Cells by HHV-8  
Ethel Cesarman, M.D., Ph.D., *Weill Medical College of Cornell University*
- S12 HHV-8 Infection and Growth Regulation of Dermal Microvascular Endothelial Cells  
Ashlee Moses, Ph.D., *Oregon Health Sciences University*
- 2:25 PM Break

- 2:45 PM-4:30 PM     **ABSTRACT PRESENTATIONS - KSHV/HHV-8: Transmission and In Vitro Virus/Cell Interactions**  
Moderators:  
Parkash Gill, M.D., *University of Southern California and Norris Cancer Hospital*  
James Goedert, M.D., *National Cancer Institute*
- 2:45 PM     4     Evidence of Blood-borne Transmission of HHV-8 Among Women With HIV Risk Behaviors  
Michael Cannon, M.S., *Centers for Disease Control and Prevention*
- 3:00 PM     5     Mixed Latent and Lytic Cycle Infection of Primary Human Dermal Microvascular Endothelial Cells With HHV-8 Derived from the JCS1 PEL Cell Line  
Gary Hayward, Ph.D., *Johns Hopkins School of Medicine*
- 3:15 PM     6     HHV-8/KSHV Regulation of Endothelial Cell Growth and Differentiation Pathways  
Ashlee Moses, Ph.D., *Oregon Health Sciences University*
- 3:30 PM     7     Characterization of Hematopoietic Progenitor Cells Following in Vitro Infection by KSHV  
Judy Mikovits, Ph.D., *SAIC Frederick, Frederick Cancer Research and Development Center, National Cancer Institute*
- 3:45 PM     8     Infection of Endothelial Cells with HHV-8 Leads to Induction of Cellular Antiviral Genes  
Margaret Offerman, M.D., Ph.D., *Emory University*
- 4:00 PM     9     Infection of HHV-8-infected B Cell Lines With Cell-free HIV-1 Through the CXCR4 Chemokine Receptor  
Elizabeth Read-Connole, M.S., Ph.D., *National Cancer Institute*
- 4:15 PM     10     The KSHV Latency-Associated Nuclear Antigen Mediates Episome Persistence Through Cis-acting KSHV Terminal Repeat (TR) DNA and Specifically Binds TR Sequence  
Kenneth Kaye, M.D., *Brigham and Women's Hospital, Harvard Medical School*
- 4:30 PM-5:00 PM     **Authors at posters**
- 4:30 PM-5:45 PM     **RECEPTION**

## May 17

- 8:00 AM- 6:30 PM     **POSTER PRESENTATIONS** (Abstract Numbers 45 to 74), First Floor Concourse
- 8:30 AM     S13     **PLENARY LECTURE**  
Translational Development of Vaccines Against B-Cell Malignancies  
Larry Kwak, M.D., *National Cancer Institute*

- 8:55 AM-9:40 AM     **ABSTRACT PRESENTATIONS - Lymphomas: Transplantation and Clinical Aspects**  
Moderator:  
Alexandra Levine, M.D., *University of Southern California and Norris Cancer Hospital*
- 8:55 AM     35     Bone Marrow Transplant Recipient Post-transplantation Lymphoproliferative Disorders Differ From Those in Solid Organ Transplant Recipients  
Amy Chadburn, M.D., *Weill School of Medicine of Cornell University*
- 9:10 AM     36     TCL-1 Oncoprotein Expression and VH Gene Sequences in Primary Central Nervous Lymphoma  
Luigi Larocca, M.D., *Catholic University of Rome, Italy*
- 9:25 AM     37     Treatment of Relapsed/Refractory AIDS-related Lymphomas With High Dose Cytarabine (ARA-C) Cisplatin Combination Regimens  
Alexandra Levine, M.D., *University of Southern California and Norris Cancer Hospital*
- 9:40 AM     S14     **PLENARY LECTURE**  
Gamma Herpesvirus Targets for Therapy  
Elliott Kieff, M.D., *Harvard University*
- 10:05 AM     Break
- 10:25 AM     **ROUNDTABLE - New Directions in AIDS Lymphoma Treatment**  
Chairs:  
Richard Ambinder, M.D., Ph.D., *Johns Hopkins University*  
David Scadden, M.D., *Harvard University*
- Panelists:
- S15     Infusional Cyclophosphamide, Doxorubicin, and Etoposide in HIV-Associated Non-Hodgkin's Lymphoma: A Review of the Einstein, Aviano, and ECOG Experience in 182 Patients  
Joseph Sparano, M.D., *Montefiore Cancer Center*
- S16     Dose-Adjusted EPOCH Chemotherapy With Suspension of Antiretroviral Therapy for HIV-Associated Non-Hodgkin's Lymphoma  
Richard Little, M.D., *National Cancer Institute*
- S17     Dose Adjusted Treatment in AIDS-Related Lymphoma  
Umberto Tirelli, M.D., *Aviano Cancer Center, Italy*
- S18     Non-Myeloablative Bone Marrow Transplantation in the Treatment of Refractory Lymphomas  
Megan Sykes, M.D., *Harvard Medical School*
- S19     Treatment of AIDS Lymphoma With High-Dose Chemotherapy and Genetically Modified Stem Cells: A Model for Evaluation of Gene Therapy  
John Zaia, M.D., *City of Hope National Medical Center*

- 11:55 AM Lunch (on your own)
- 1:25 PM-2:10 PM **ABSTRACT PRESENTATIONS - Lymphomas: KSHV/HHV-8**  
Moderator: Richard Ambinder, M.D., Ph.D., *Johns Hopkins University*
- 1:25 PM 38 High Incidence of Non-Hodgkin's Lymphoma in HIV/HHV-8 Associated Castleman's Disease  
Eric Oksenhender, M.D., *Hospital Saint-Louis, France*
- 1:40 PM 39 Proliferation in HHV-8 Positive Primary Effusion Lymphomas is Associated With Expression of HHV-8 Cyclin but Independent of P27/KIP1  
Antonino Carbone, M.D., *Centro di Riferimento Oncologico-Aviano and Istituto Nazionale Tumori, Italy*
- 1:55 PM 40 Pharmacologic Induction of Lytic Infection: A Novel Therapeutic Strategy for EBV- and KSHV-associated Malignancies  
Jennifer Cannon, M.S., *Johns Hopkins University School of Medicine*
- 2:10 PM **ROUNDTABLE - KSHV/HHV-8 in Post-transplant Kaposi's Sarcoma**  
Chairs:  
Kenneth Cremer, Ph.D., *National Cancer Institute*  
Thomas Schulz, M.D., *University of Liverpool, United Kingdom*
- S20 Panelists:  
Viral Infection and Malignancy in the Organ Transplant Recipient  
Jay Fishman, M.D. *Massachusetts General Hospital*
- S21 Risk Estimates and Subsequent Therapeutic Strategies in Posttransplant Kaposi's Sarcoma  
Dominique Farge, M.D., *Hospital Saint-Louis, France*
- Risk of Kaposi's Sarcoma Development in Renal Transplant Patients from Northern Italy  
Carlo Parravicini, M.D., *L. Sacco Hospital, Italy*
- S22 Evidence for Reactivation of HHV-8 Among Solid Organ But Not Bone Marrow Transplant Patients  
Frank Jenkins, Ph.D., *University of Pittsburgh Cancer Institute*
- S23 Prevalence of Antibodies to HHV-8 in Saudi Arabians Patients With and Without Renal Failure  
George Miller, M.D., *Yale University School of Medicine*
- S24 Non Malignant Disease Associated With HHV-8 Infection in Peripheral Blood Stem Cell and Renal Transplant Patients From Italy  
Mario Luppi, M.D., Ph.D., *University of Modena, Italy*
- 3:30 PM Break

- 3:50 PM-4:50 PM     **ABSTRACT PRESENTATIONS - KSHV/HHV-8: Molecular Biology**  
Moderator:  
Thomas Schulz, M.D., *University of Liverpool, United Kingdom*
- 3:50 PM     41     KSHV Impairs Antigen Presentation in Latently Infected Cells  
Christian Brander, Ph.D., *Massachusetts General Hospital*
- 4:05 PM     42     HHV-8 Open Reading Frame K1 Signals Through NFκB and Activates Cells  
Felipe Samaniego, M.D., *M.D. Anderson Cancer Center*
- 4:20 PM     43     Novel HHV-8/CDK6 Kinase Substrates  
Rukiyah Van Dross, Ph.D., *Vanderbilt University*
- 4:35 PM     44     Signal Transduction Pathways Involved in Reactivation of HHV-8 in Latently-infected Cells: Evidence for Distinct Calcineurin- and Protein Kinase C-dependent Pathways  
Paul Zoetewij, Ph.D., *National Cancer Institute*
- 4:50 PM-5:20 PM     **Authors at posters**
- 4:50 PM-6:00 PM     **RECEPTION**

## May 18

- 8:30 AM     **ROUNDTABLE - Approaches to Monitoring Therapy With Anti-angiogenesis Agents**  
Chairs:  
Ellen Feigal, M.D., *National Cancer Institute*  
Michal Neeman, Ph.D., *The Weizmann Institute of Science, Israel*
- Panelists:  
Angiogenesis: Clinical Perspectives  
James Pluda, M.D., *National Cancer Institute*
- Ultrasound in Evaluating Angiogenesis  
Kathy Ferrara, Ph.D., *University of California, Davis*
- S25     Monitoring Activity in Lesions of Kaposi's Sarcoma Using Infra-red Images  
Jerry Williams, Ph.D., *Johns Hopkins University*
- 9:40 AM     **PLENARY LECTURE**  
S26     Human Papillomavirus Infections in HIV Positive Adolescents  
Anna-Barbara Moscicki, M.D., *University of California, San Francisco*
- 10:05 AM     Break
- 10:20 AM-11:05 AM     **ABSTRACT PRESENTATIONS - Clinical Approaches**  
Moderators:  
Joel Palefsky, M.D., F.C.R.P., *University of California, San Francisco*  
Robert Yarchoan, M.D., *National Cancer Institute*

- 10:20 AM 75      Angiogenesis Inhibitor Col-3 in the Treatment of HIV-related Kaposi's Sarcoma: a Phase I AIDS Malignancy Consortium Study  
Mary Cianfrocca, D.O., *Fox Chase Cancer Center*
- 10:35 AM 76      Treatment of Human Papillomavirus Type 16 Virus-infected Cells Using the Herpes Simplex Virus Thymidine Kinase Gene  
Neerja Sethi, Ph.D., *University of California, San Francisco*
- 10:50 AM 77      Detection of Human Polyomavirus JC in Pediatric HIV-Associated Cancers  
Bruce Shiramizu, M.D., *University of Hawaii at Manoa*

**PLENARY LECTURE/DISCUSSION**

- 11:05 AM           Anal Squamous Intraepithelial Lesions: Therapeutic Challenges and Opportunities Session  
Joel Palefsky, M.D., F.C.R.P., *University of California, San Francisco*
- 11:45 AM           Lunch (on your own)
- 12:45 PM-3:30 PM   **CURRENT SCIENCE IN SEROLOGIC TECHNIQUES FOR DETECTION OF KSHV/HHV-8**  
**Sponsored by the Biological Carcinogenesis Branch, Division of Cancer Biology, National Cancer Institute**  
Chairs:  
Kenneth Cremer, Ph.D., *National Cancer Institute*  
Patrick Moore, M.D., M.P.H., *Columbia University*
- 78                 Speakers:  
Serological Assays for KSHV Based on Recombinant Viral Proteins  
Thomas F. Schulz, M.D., *University of Liverpool, United Kingdom*
- 79                 Comparison of HHV-8 Serologic Assays and Development of an Algorithm for HHV-8 Serodiagnosis  
Frank Neipel, Ph.D., *Universitat Erlangen, Germany*
- 80                 HHV-8 Peptide ELISA  
Octavian Schatz, Ph.D., *DIIVIR Limited, Germany*
- 81                 Selection of Reference Groups and Cut-points in the Development of HHV-8 Serologic Assays  
Jeffrey Martin, M.D., M.P.H., *University of California, San Francisco*
- 82                 Serological Responses to HHV-8  
Bala Chandran, Ph.D., *University of Kansas Medical Center*
- 83                 Serologic Assays for Detection of HHV-8 Antibodies  
Philip E. Pellett, Ph.D., *Centers for Disease Control and Prevention*
- 84                 Performance of HHV-8 Serological Assays for Testing Sera from Diverse Populations: Assay Development  
Denise Whitby, Ph.D., *Frederick Cancer Research and Development Center, National Cancer Institute*

- 84 Performance of HHV-8 Serological Assays for Testing Sera from Diverse Populations:  
Data Analysis  
Eric Engels, M.D., M.P.H., *National Cancer Institute*
- 85 KSHV Serology in Europe and Uganda: A Multicentric Study with Multiple and Novel  
Assays  
Paolo Monini, Ph.D., *Instituto Superiore de Sanita, Italy*
- 86 Multicenter Comparison of HHV-8 Serologic Assays and Assessment of HHV-8  
Seroprevalence in US Blood Donors  
Philip E. Pellett, Ph.D., *Centers for Disease Control and Prevention*